Skip to main content

Table 3 Effective rate according to the ACR20, ACR50, and ACR70

From: A multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Tong Luo Hua Shi capsule, a modernized Tibetan medicine, in patients with rheumatoid arthritis

 

FAS, n (%)

PPS, n (%)

ACR70

ACR50

ACR20

ACR70

ACR50

ACR20

TLHS 4.8 g

6 (10.2)

24 (40.7)**,****

45 (76.3)*,***

6 (11.3)

23 (43.4)**,****

44 (83.0)**,****

TLHS 3.6 g

2 (3.4)

14 (23.7)

43 (72.9)*

2 (3.7)

14 (25.9)

42 (77.8)*,***

TLHS 2.4 g

1 (1.7)

9 (15.3)

33 (55.9)

1 (1.8)

9 (15.8)

33 (57.9)

Placebo

3 (5.1)

8 (13.6)

32 (54.2)

3 (5.8)

8 (15.4)

29 (55.8)

  1. ACR American College of Rheumatology response criteria, FAS full analysis set, PPS per protocol set
  2. *P < 0.05 versus the placebo group
  3. **P < 0.01 versus the placebo group
  4. ***P < 0.05 versus the 2.4 g group
  5. ****P < 0.01 versus the 2.4 g group
Back to article page

Trials

ISSN: 1745-6215